Gilead Sciences Inc (GILD) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GILD SEC filings page.
Gilead Sciences Inc (GILD) reported $30.5B in revenue over the twelve months to Jun 30, 2026, up 5.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Gilead’s revenue is steady, but operating earnings swing sharply while cash flow remains resilient and leverage moves lower.
The sharp FY2024 earnings trough did not translate into a cash-flow trough: net income was$480M while operating cash flow was$10.8B . In FY2025, net income recovered to$8.5B and operating cash flow remained$10.0B , showing that reported profit was unusually noisy relative to the company’s cash economics.
Gross margin was
Debt-to-equity fell from 1.3x to 1.0x in FY2025, indicating a less debt-heavy capital structure. The company returned
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Gilead Sciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Gilead Sciences Inc has an operating margin of 34.0%, meaning the company retains $34 of operating profit per $100 of revenue. This strong profitability earns a score of 81/100, reflecting efficient cost management and pricing power. This is up from 5.8% the prior year.
Gilead Sciences Inc's revenue grew a modest 2.4% year-over-year to $29.4B. This slow but positive growth earns a score of 46/100.
Gilead Sciences Inc has a moderate D/E ratio of 0.97. This balance of debt and equity financing earns a leverage score of 44/100.
Gilead Sciences Inc's current ratio of 1.55 indicates adequate short-term liquidity, earning a score of 44/100. The company can meet its near-term obligations, though with limited headroom.
Gilead Sciences Inc converts 32.1% of revenue into free cash flow ($9.5B). This strong cash generation earns a score of 95/100.
Gilead Sciences Inc earns a strong 37.5% return on equity (ROE), meaning it generates $37 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 74/100. This is up from 2.5% the prior year.
Gilead Sciences Inc scores 4.48, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($179.5B) relative to total liabilities ($36.3B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Gilead Sciences Inc passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Gilead Sciences Inc generates $1.18 in operating cash flow ($10.0B OCF vs $8.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Gilead Sciences Inc earns $9.79 in operating income for every $1 of interest expense ($10.0B vs $1.0B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Gilead Sciences Inc generated $7.8B in revenue in Q2 2026. This represents an increase of 10.2% from the same quarter a year earlier. Against the prior quarter it is up 12.1%.
Gilead Sciences Inc's EBITDA was -$10.3B in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 501.1% from the same quarter a year earlier. Against the prior quarter it is down 484.3%.
Gilead Sciences Inc reported -$10.5B in net income in Q2 2026. This represents a decrease of 635.5% from the same quarter a year earlier. Against the prior quarter it is down 619.3%.
Gilead Sciences Inc earned -$8.45 per diluted share (EPS) in Q2 2026. This represents a decrease of 641.7% from the same quarter a year earlier. Against the prior quarter it is down 624.8%.
Cash & Balance Sheet
Gilead Sciences Inc generated $3.4B in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 376.8% from the same quarter a year earlier. Against the prior quarter it is up 41.5%.
Gilead Sciences Inc held $3.2B in cash against $23.8B in long-term debt as of Q2 2026.
Gilead Sciences Inc paid $0.82 per share in dividends in Q2 2026. This represents an increase of 3.8% from the same quarter a year earlier. It is unchanged from the prior quarter.
Margins & Returns
Gilead Sciences Inc's gross margin was 79.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
Gilead Sciences Inc's ROE was -88.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 98.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 97.3 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Gilead Sciences Inc invested $1.8B in research and development in Q2 2026. This represents an increase of 18.3% from the same quarter a year earlier. Against the prior quarter it is up 28.6%.
Gilead Sciences Inc spent $355.0M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 32.6% from the same quarter a year earlier. Against the prior quarter it is down 15.3%.
Gilead Sciences Inc invested $140.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 30.8% from the same quarter a year earlier. Against the prior quarter it is up 19.7%.
GILD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8B+10.2% | $7.0B+4.4% | $7.9B+4.7% | $7.8B+3.0% | $7.1B+1.8% | $6.7B-0.3% | $7.6B+6.4% | $7.5B+7.0% |
| Cost of Revenue | $1.6B+5.2% | $1.4B-6.2% | $1.6B+2.7% | $1.6B-0.3% | $1.5B-2.8% | $1.5B-0.8% | $1.6B-24.4% | $1.6B+0.6% |
| Gross Profit | $6.2B+11.5% | $5.5B+7.6% | $6.3B+5.2% | $6.2B+3.8% | $5.6B+3.2% | $5.1B-0.1% | $6.0B+19.2% | $6.0B+8.8% |
| R&D Expenses | $1.8B+18.3% | $1.4B-0.5% | $1.6B-3.5% | $1.3B-3.5% | $1.5B+10.4% | $1.4B-9.3% | $1.6B+16.6% | $1.4B-4.3% |
| SG&A Expenses | $1.9B+40.7% | $1.5B+15.3% | $1.8B-5.9% | $1.4B-5.3% | $1.4B-0.9% | $1.3B-8.5% | $1.9B+18.6% | $1.4B+9.0% |
| Operating Income | -$10.4B-520.1% | $2.6B+15.6% | $2.0B-19.1% | $3.3B+274.7% | $2.5B-6.4% | $2.2B+151.8% | $2.5B+52.1% | $888.0M-66.1% |
| EBITDA | -$10.3B-501.1% | $2.7B+14.8% | $4.5B-9.6% | $3.4B+248.0% | $2.6B-6.4% | $2.3B+155.2% | $4.9B+118.8% | $982.0M-70.3% |
| Interest Expense | $247.0M-2.8% | $240.0M-7.7% | $254.0M+2.4% | $256.0M+7.6% | $254.0M+7.2% | $260.0M+2.4% | $248.0M-1.6% | $238.0M+2.6% |
| Income Tax | $242.0M-48.3% | $559.0M+67.4% | -$105.0M-127.3% | $589.0M+298.3% | $468.0M+6.8% | $334.0M+206.0% | $385.0M+63.1% | -$297.0M-303.4% |
| Net Income | -$10.5B-635.5% | $2.0B+53.7% | $2.2B+22.4% | $3.1B+143.6% | $2.0B+21.4% | $1.3B+131.5% | $1.8B+24.7% | $1.3B-42.5% |
| EPS (Basic) | -$8.45-638.2% | $1.63+53.8% | $1.76+23.9% | $2.46+146.0% | $1.57+21.7% | $1.06+131.7% | $1.42+23.5% | $1.00-42.9% |
| EPS (Diluted) | -$8.45-641.7% | $1.61+54.8% | $1.74+22.5% | $2.43+143.0% | $1.56+20.9% | $1.04+131.1% | $1.42+25.7% | $1.00-42.2% |
| Diluted Shares (Avg) | 1.24B-1.0% | 1.25B-0.4% | N/A | 1.25B0.0% | 1.25B+0.3% | 1.26B+1.0% | N/A | 1.25B-0.2% |
GILD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $49.4B-11.4% | $56.3B-0.3% | $59.0B0.0% | $58.5B+7.4% | $55.7B+4.0% | $56.4B+0.3% | $59.0B-5.0% | $54.5B-12.6% |
| Current Assets | $13.9B-5.3% | $18.6B+10.3% | $18.3B-4.3% | $17.9B+20.9% | $14.7B+19.5% | $16.9B+20.4% | $19.2B+19.2% | $14.8B-7.5% |
| Cash & Equivalents | $3.2B-38.2% | $7.6B-3.8% | $7.6B-24.3% | $7.3B+45.5% | $5.1B+85.6% | $7.9B+68.0% | $10.0B+64.2% | $5.0B-11.7% |
| Short-Term Investments | $0-100.0% | $15.0M | $68.0M | $19.0M | $69.0M | $0 | $0-100.0% | $0-100.0% |
| Inventory | $2.0B+7.0% | $1.9B+8.8% | $1.8B+3.7% | $1.8B-4.5% | $1.8B-9.9% | $1.8B-5.1% | $1.7B-4.3% | $1.9B+12.4% |
| Accounts Receivable | $5.1B+5.7% | $4.7B+8.0% | $4.9B+11.2% | $5.1B+11.1% | $4.8B+2.5% | $4.4B-6.0% | $4.4B-5.2% | $4.6B-4.2% |
| Long-Term Investments | $0-100.0% | $983.0M | $3.0B | $2.0B | $1.9B | $0 | $0-100.0% | $0-100.0% |
| Goodwill | $8.3B0.0% | $8.3B0.0% | $8.3B0.0% | $8.3B0.0% | $8.3B0.0% | $8.3B0.0% | $8.3B0.0% | $8.3B0.0% |
| Total Liabilities | $37.5B+4.1% | $32.8B-12.1% | $36.3B-8.4% | $37.0B+2.6% | $36.0B+2.1% | $37.3B-3.8% | $39.7B+0.9% | $36.0B-10.0% |
| Current Liabilities | $11.0B-1.5% | $9.5B-23.2% | $11.8B-1.6% | $12.3B+4.9% | $11.2B+3.8% | $12.3B-5.2% | $12.0B+6.4% | $11.7B-1.8% |
| Non-Current Liabilities | $26.5B+6.7% | $23.3B-6.6% | $24.5B-11.4% | $24.7B+1.5% | $24.9B+1.4% | $24.9B-3.1% | $27.7B-1.3% | $24.3B-13.5% |
| Long-Term Debt | $23.8B+7.6% | $20.9B-5.8% | $22.1B-11.1% | $22.1B+3.3% | $22.1B+2.8% | $22.1B+2.9% | $24.9B+7.4% | $21.4B-7.6% |
| Total Equity | $11.8B-39.9% | $23.5B+22.7% | $22.7B+17.4% | $21.5B+16.6% | $19.7B+7.6% | $19.2B+9.3% | $19.3B-15.3% | $18.5B-17.2% |
| Retained Earnings | $2.2B-80.6% | $14.1B+29.3% | $13.7B+19.4% | $12.8B+15.8% | $11.3B+1.4% | $10.9B+2.6% | $11.5B-29.5% | $11.1B-30.8% |
GILD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.6B+332.0% | $2.5B+44.8% | $3.3B+11.8% | $4.1B-4.7% | $827.0M-37.6% | $1.8B-20.8% | $3.0B+37.2% | $4.3B+145.5% |
| Depreciation & Amortization | $98.0M+5.4% | $93.0M-4.1% | $90.0M-5.3% | $90.0M-4.3% | $93.0M-5.1% | $97.0M+3.2% | $95.0M-86.3% | $94.0M-86.3% |
| Stock-Based Compensation | N/A | $218.0M+4.3% | N/A | N/A | N/A | $209.0M+11.8% | N/A | N/A |
| Capital Expenditures | $140.0M+30.8% | $117.0M+12.5% | $205.0M+39.5% | $147.0M+4.3% | $107.0M-17.7% | $104.0M-1.0% | $147.0M-31.6% | $141.0M+15.6% |
| Free Cash Flow | $3.4B+376.8% | $2.4B+46.8% | $3.1B+10.4% | $4.0B-5.0% | $720.0M-39.7% | $1.7B-21.8% | $2.8B+44.7% | $4.2B+155.2% |
| Investing Cash Flow | -$10.3B-389.0% | $1.8B+526.5% | -$1.8B-715.6% | -$427.0M+39.9% | -$2.1B-589.3% | -$415.0M+81.2% | -$225.0M+69.1% | -$710.0M-210.0% |
| Financing Cash Flow | $2.3B+249.6% | -$4.2B-23.7% | -$1.3B-155.9% | -$1.5B-8.0% | -$1.6B+46.9% | -$3.4B-151.7% | $2.3B+305.6% | -$1.4B+9.2% |
| Dividends Paid | $1.0B+3.4% | $1.0B+3.0% | $994.0M+2.2% | $995.0M+1.8% | $997.0M+1.9% | $1.0B+2.0% | $973.0M+3.2% | $977.0M+2.5% |
| Share Buybacks | $355.0M-32.6% | $419.0M-42.6% | $230.0M-34.3% | $435.0M+45.0% | $527.0M+427.0% | $730.0M+82.5% | $350.0M+133.3% | $300.0M0.0% |
GILD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.8%+0.9pp | 79.2%+2.3pp | 79.5%+0.4pp | 79.8%+0.7pp | 78.8%+1.0pp | 76.9%+0.1pp | 79.1%+8.5pp | 79.1%+1.3pp |
| Operating Margin | -133.2% | 37.2%+3.6pp | 25.0%-7.4pp | 42.8%+31.1pp | 34.9%-3.1pp | 33.6%+98.2pp | 32.4%+9.7pp | 11.8%-25.4pp |
| Net Margin | -134.5% | 29.0%+9.3pp | 27.6%+4.0pp | 39.3%+22.7pp | 27.7%+4.5pp | 19.7%+82.1pp | 23.6%+3.5pp | 16.6%-14.3pp |
| Return on Equity | -88.7%-98.7pp | 8.6%+1.7pp | 9.6%+0.4pp | 14.2%+7.4pp | 10.0%+1.1pp | 6.9%+30.6pp | 9.2%+3.0pp | 6.8%-3.0pp |
| Return on Assets | -21.3%-24.8pp | 3.6%+1.3pp | 3.7%+0.7pp | 5.2%+2.9pp | 3.5%+0.5pp | 2.3%+9.7pp | 3.0%+0.7pp | 2.3%-1.2pp |
| Current Ratio | 1.270.0x | 1.97+0.6x | 1.550.0x | 1.45+0.2x | 1.32+0.2x | 1.37+0.3x | 1.60+0.2x | 1.26-0.1x |
| Debt-to-Equity | 2.01+0.9x | 0.89-0.3x | 0.97-0.3x | 1.03-0.1x | 1.13-0.1x | 1.16-0.1x | 1.29+0.3x | 1.16+0.1x |
| Asset Turnover | 0.160.0x | 0.120.0x | 0.130.0x | 0.130.0x | 0.130.0x | 0.120.0x | 0.130.0x | 0.140.0x |
| FCF Margin | 44.0%+33.8pp | 34.9%+10.1pp | 39.4%+2.0pp | 51.0%-4.3pp | 10.2%-7.0pp | 24.8%-6.8pp | 37.4%+9.9pp | 55.2%+32.1pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Gilead Sciences Inc GILD | FY2025 | $29.4B | $8.5B | 28.9% | $179.5B | 64/100 |
| Amgen Inc AMGN | FY2025 | $36.8B | $7.7B | 21.0% | $217.9B | 63/100 |
| Pfizer Inc. PFE | FY2025 | $62.6B | $7.8B | 12.4% | $158.5B | 33/100 |
| Bristol-Myers Squibb Co. BMY | FY2025 | $48.2B | $7.1B | 14.6% | $124.9B | 33/100 |
Where Gilead Sciences Inc Ranks
Frequently Asked Questions
What is Gilead Sciences Inc's annual revenue?
Gilead Sciences Inc (GILD) reported $29.4B in total revenue for fiscal year 2025. This represents a 2.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Gilead Sciences Inc's revenue growing?
Gilead Sciences Inc (GILD) revenue grew by 2.4% year-over-year, from $28.8B to $29.4B in fiscal year 2025.
Is Gilead Sciences Inc profitable?
Yes, Gilead Sciences Inc (GILD) reported a net income of $8.5B in fiscal year 2025, with a net profit margin of 28.9%.
What is Gilead Sciences Inc's EBITDA?
Gilead Sciences Inc (GILD) had EBITDA of $12.8B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Gilead Sciences Inc have?
As of fiscal year 2025, Gilead Sciences Inc (GILD) had $7.6B in cash and equivalents against $22.1B in long-term debt.
What is Gilead Sciences Inc's gross margin?
Gilead Sciences Inc (GILD) had a gross margin of 78.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Gilead Sciences Inc's operating margin?
Gilead Sciences Inc (GILD) had an operating margin of 34.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Gilead Sciences Inc's net profit margin?
Gilead Sciences Inc (GILD) had a net profit margin of 28.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Gilead Sciences Inc pay dividends?
Yes, Gilead Sciences Inc (GILD) paid $3.16 per share in dividends during fiscal year 2025.
What is Gilead Sciences Inc's return on equity (ROE)?
Gilead Sciences Inc (GILD) has a return on equity of 37.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Gilead Sciences Inc's free cash flow?
Gilead Sciences Inc (GILD) generated $9.5B in free cash flow during fiscal year 2025. This represents a -8.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Gilead Sciences Inc's operating cash flow?
Gilead Sciences Inc (GILD) generated $10.0B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Gilead Sciences Inc's total assets?
Gilead Sciences Inc (GILD) had $59.0B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Gilead Sciences Inc's capital expenditures?
Gilead Sciences Inc (GILD) invested $563.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Gilead Sciences Inc spend on research and development?
Gilead Sciences Inc (GILD) invested $5.8B in research and development during fiscal year 2025.
What is Gilead Sciences Inc's current ratio?
Gilead Sciences Inc (GILD) had a current ratio of 1.55 as of fiscal year 2025, which is generally considered healthy.
What is Gilead Sciences Inc's debt-to-equity ratio?
Gilead Sciences Inc (GILD) had a debt-to-equity ratio of 0.97 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Gilead Sciences Inc's return on assets (ROA)?
Gilead Sciences Inc (GILD) had a return on assets of 14.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Gilead Sciences Inc's P/E ratio?
Gilead Sciences Inc (GILD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $179.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Gilead Sciences Inc's price-to-sales ratio?
Gilead Sciences Inc (GILD) trades at 5.9x sales, its market capitalization divided by revenue of $30.5B revenue, trailing 12 months to June 30, 2026. The market capitalization is $179.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Gilead Sciences Inc's Altman Z-Score?
Gilead Sciences Inc (GILD) has an Altman Z-Score of 4.48, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Gilead Sciences Inc's Piotroski F-Score?
Gilead Sciences Inc (GILD) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Gilead Sciences Inc's earnings high quality?
Gilead Sciences Inc (GILD) has an earnings quality ratio of 1.18x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Gilead Sciences Inc cover its interest payments?
Gilead Sciences Inc (GILD) has an interest coverage ratio of 9.79x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Gilead Sciences Inc?
Gilead Sciences Inc (GILD) scores 64 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.